177 related articles for article (PubMed ID: 24947588)
1. Longer duration of combination antiretroviral therapy reduces the risk of Hodgkin lymphoma: A cohort study of HIV-infected male veterans.
Kowalkowski MA; Mims MA; Day RS; Du XL; Chan W; Chiao EY
Cancer Epidemiol; 2014 Aug; 38(4):386-92. PubMed ID: 24947588
[TBL] [Abstract][Full Text] [Related]
2. Effect of immune reconstitution on the incidence of HIV-related Hodgkin lymphoma.
Kowalkowski MA; Mims MP; Amiran ES; Lulla P; Chiao EY
PLoS One; 2013; 8(10):e77409. PubMed ID: 24098586
[TBL] [Abstract][Full Text] [Related]
3. Use of boosted protease inhibitors reduces Kaposi sarcoma incidence among male veterans with HIV infection.
Kowalkowski MA; Kramer JR; Richardson PR; Suteria I; Chiao EY
Clin Infect Dis; 2015 May; 60(9):1405-14. PubMed ID: 25586682
[TBL] [Abstract][Full Text] [Related]
4. HIV-associated Hodgkin lymphoma during the first months on combination antiretroviral therapy.
Lanoy E; Rosenberg PS; Fily F; Lascaux AS; Martinez V; Partisani M; Poizot-Martin I; Rouveix E; Engels EA; Costagliola D; Goedert JJ;
Blood; 2011 Jul; 118(1):44-9. PubMed ID: 21551234
[TBL] [Abstract][Full Text] [Related]
5. Clinical characteristics, incidence, and risk factors of HIV-related Hodgkin lymphoma in the era of combination antiretroviral therapy.
Gotti D; Danesi M; Calabresi A; Ferraresi A; Albini L; Donato F; Castelli F; Scalzini A; Quiros-Roldan E;
AIDS Patient Care STDS; 2013 May; 27(5):259-65. PubMed ID: 23600703
[TBL] [Abstract][Full Text] [Related]
6. HIV-1-related Hodgkin lymphoma in the era of combination antiretroviral therapy: incidence and evolution of CD4⁺ T-cell lymphocytes.
Bohlius J; Schmidlin K; Boué F; Fätkenheuer G; May M; Caro-Murillo AM; Mocroft A; Bonnet F; Clifford G; Paparizos V; Miro JM; Obel N; Prins M; Chêne G; Egger M;
Blood; 2011 Jun; 117(23):6100-8. PubMed ID: 21368291
[TBL] [Abstract][Full Text] [Related]
7. Outcome effects of antiretroviral drug combinations in HIV-positive patients with chemotherapy for lymphoma: a retrospective analysis.
Sombogaard F; Franssen EJF; Terpstra WE; Kerver ED; van den Berk GEL; Crul M
Int J Clin Pharm; 2018 Oct; 40(5):1402-1408. PubMed ID: 29948741
[TBL] [Abstract][Full Text] [Related]
8. Effect of immunodeficiency, HIV viral load, and antiretroviral therapy on the risk of individual malignancies (FHDH-ANRS CO4): a prospective cohort study.
Guiguet M; Boué F; Cadranel J; Lang JM; Rosenthal E; Costagliola D;
Lancet Oncol; 2009 Dec; 10(12):1152-9. PubMed ID: 19818686
[TBL] [Abstract][Full Text] [Related]
9. Hodgkin lymphoma in the Swiss HIV Cohort Study.
Clifford GM; Rickenbach M; Lise M; Dal Maso L; Battegay M; Bohlius J; Boffi El Amari E; Karrer U; Jundt G; Bordoni A; Ess S; Franceschi S;
Blood; 2009 Jun; 113(23):5737-42. PubMed ID: 19336755
[TBL] [Abstract][Full Text] [Related]
10. Incidence of herpes zoster in HIV-infected adults in the combined antiretroviral therapy era: results from the FHDH-ANRS CO4 cohort.
Grabar S; Tattevin P; Selinger-Leneman H; de La Blanchardiere A; de Truchis P; Rabaud C; Rey D; Daneluzzi V; Ferret S; Lascaux AS; Hanslik T; Costagliola D; Launay O;
Clin Infect Dis; 2015 Apr; 60(8):1269-77. PubMed ID: 25601456
[TBL] [Abstract][Full Text] [Related]
11. Cancer risk and use of protease inhibitor or nonnucleoside reverse transcriptase inhibitor-based combination antiretroviral therapy: the D: A: D study.
Bruyand M; Ryom L; Shepherd L; Fatkenheuer G; Grulich A; Reiss P; de Wit S; D Arminio Monforte A; Furrer H; Pradier C; Lundgren J; Sabin C;
J Acquir Immune Defic Syndr; 2015 Apr; 68(5):568-77. PubMed ID: 25763785
[TBL] [Abstract][Full Text] [Related]
12. Clinical characteristics of human immunodeficiency virus-associated Hodgkin lymphoma patients in Japan.
Yotsumoto M; Hagiwara S; Ajisawa A; Tanuma J; Uehira T; Nagai H; Fujikawa Y; Maeda S; Kitano K; Arima N; Uno K; Iwai T; Hongo I; Ota Y; Fukutake K; Okada S
Int J Hematol; 2012 Aug; 96(2):247-53. PubMed ID: 22752537
[TBL] [Abstract][Full Text] [Related]
13. Differences in Virological and Immunological Risk Factors for Non-Hodgkin and Hodgkin Lymphoma.
Shepherd L; Ryom L; Law M; Hatleberg CI; de Wit S; Monforte AD; Battegay M; Phillips A; Bonnet F; Reiss P; Pradier C; Grulich A; Sabin C; Lundgren J; Mocroft A
J Natl Cancer Inst; 2018 Jun; 110(6):598-607. PubMed ID: 29267895
[TBL] [Abstract][Full Text] [Related]
14. Exposure to antiretroviral therapy and risk of cancer in HIV-infected persons.
Chao C; Leyden WA; Xu L; Horberg MA; Klein D; Towner WJ; Quesenberry CP; Abrams DI; Silverberg MJ
AIDS; 2012 Nov; 26(17):2223-31. PubMed ID: 22951631
[TBL] [Abstract][Full Text] [Related]
15. Cancer risk in HIV-infected people in the USA from 1996 to 2012: a population-based, registry-linkage study.
Hernández-Ramírez RU; Shiels MS; Dubrow R; Engels EA
Lancet HIV; 2017 Nov; 4(11):e495-e504. PubMed ID: 28803888
[TBL] [Abstract][Full Text] [Related]
16. High Risk Features Contrast With Favorable Outcomes in HIV-associated Hodgkin Lymphoma in the Modern cART Era, ANRS CO16 LYMPHOVIR Cohort.
Besson C; Lancar R; Prevot S; Brice P; Meyohas MC; Marchou B; Gabarre J; Bonnet F; Goujard C; Lambotte O; Boué F; Mounier N; Partisani M; Raffi F; Costello R; Hendel-Chavez H; Algarte-Genin M; Trabelsi S; Marchand L; Raphael M; Taoufik Y; Costagliola D
Clin Infect Dis; 2015 Nov; 61(9):1469-75. PubMed ID: 26223997
[TBL] [Abstract][Full Text] [Related]
17. Incidence, Treatment, and Outcome of HIV-Associated Hematologic Malignancies in People Living with HIV in Sweden.
Kieri O; Marrone G; Sönnerborg A; Nowak P
AIDS Res Hum Retroviruses; 2022 Feb; 38(2):135-142. PubMed ID: 34652958
[TBL] [Abstract][Full Text] [Related]
18. Association of Viral Suppression With Lower AIDS-Defining and Non-AIDS-Defining Cancer Incidence in HIV-Infected Veterans: A Prospective Cohort Study.
Park LS; Tate JP; Sigel K; Brown ST; Crothers K; Gibert C; Goetz MB; Rimland D; Rodriguez-Barradas MC; Bedimo RJ; Justice AC; Dubrow R
Ann Intern Med; 2018 Jul; 169(2):87-96. PubMed ID: 29893768
[TBL] [Abstract][Full Text] [Related]
19. Cancer risk in the Swiss HIV Cohort Study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy.
Clifford GM; Polesel J; Rickenbach M; Dal Maso L; Keiser O; Kofler A; Rapiti E; Levi F; Jundt G; Fisch T; Bordoni A; De Weck D; Franceschi S;
J Natl Cancer Inst; 2005 Mar; 97(6):425-32. PubMed ID: 15770006
[TBL] [Abstract][Full Text] [Related]
20. Risk of non-AIDS-defining cancers among HIV-1-infected individuals in France between 1997 and 2009: results from a French cohort.
Hleyhel M; Hleyhel M; Bouvier AM; Belot A; Tattevin P; Pacanowski J; Genet P; De Castro N; Berger JL; Dupont C; Lavolé A; Pradier C; Salmon D; Simon A; Martinez V; Spano JP; Costagliola D; Grabar S;
AIDS; 2014 Sep; 28(14):2109-18. PubMed ID: 25265077
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
